Source: Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
R. Pirker (Vienna, Austria). PRO: maintenance is cost-effective. Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"

Member's Comments

No comment yet.

Related content which might interest you: PRO recommendation Source: ERS Course 2018 - Noninvasive ventilation: advanced Year: 2018 CON: maintenance is not cost-effective Source: Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC" Year: 2012 From kitchen table questionnaires to valid PRO: how PRO's can provide insight in clinical events, the EXACT-PRO example Source: Annual Congress 2012 - An ERS/ELF joint session "New tools to assess improvement in respiratory patients: capturing the patient's perspective" Year: 2012 Use of antifibrotics in post-COVID ILD: PRO Source: Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease? Year: 2021 PRO: Severity scores are useful Source: Annual Congress 2012 - Pro-Con Debate "Severe community-acquired pneumonia: a lung disease?" Year: 2012 Is there a place for oral mucolytics in the prevention of LRTI? - PRO Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 PRO - Steroids in ARDS Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020 Long term application of NIV in COPD - PRO & CON Source: ERS course 2015 Year: 2015 Debate: Antibiotic treatment is contraindicated in acute bronchitis - PRO Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis Year: 2008 NIV and pneumonia - PRO & CON Source: ERS course 2015 Year: 2015 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Asthma control: which tools are feasible in primary care? Source: Annual Congress 2013 –Primary Care Programme "Asthma management in clinical practice" Year: 2013 Analysis of the patient-reported outcome (PRO) endpoints found in labeling claims of asthma drugs in Europe Source: Eur Respir J 2007; 30: Suppl. 51, 193s Year: 2007